Literature DB >> 33933504

Patient Preferences and Treatment Decisions for Prostate Cancer: Results From A Statewide Urological Quality Improvement Collaborative.

Roshan Paudel1, Stephanie Ferrante2, Ji Qi2, Rodney L Dunn2, Donna L Berry3, Alice Semerjian4, Christopher M Brede5, Arvin K George6, Brian R Lane5, Kevin B Ginsburg7, James E Montie6, Giulia I Lane8.   

Abstract

OBJECTIVES: To examine the relationship between influential factors and treatment decisions among men with newly diagnosed prostate cancer (PCa).
METHODS: We identified men in the Michigan Urological Surgery Improvement Collaborative registry diagnosed with localized PCa between 2018-2020 who completed Personal Patient Profile-Prostate. We analyzed the proportion of active surveillance (AS) between men who stated future bladder, bowel, and sexual problems (termed influential factors) had "a lot of influence" on their treatment decisions versus other responses. We also assessed the relationship between influential factors, confirmatory testing results and choice of AS.
RESULTS: A total of 509 men completed Personal Patient Profile-Prostate. Treatment decisions aligned with influential factors for 88% of men with favorable risk and 49% with unfavorable risk PCa. A higher proportion of men who identified bladder, bowel and sexual concerns as having "a lot of influence" on their treatment decision chose AS, compared with men with other influential factors, although not statistically significant (44% vs 35%, P = .11). Similar results were also found when men were stratified based on PCa risk groups (favorable risk: 78% vs 67%; unfavorable risk: 17% vs 9%, respectively). Despite a small sample size, a higher proportion of men with non-reassuring confirmatory testing selected AS if influential factors had "a lot of influence" compared to "no influence" on their treatment decisions.
CONCLUSION: Men's concerns for future bladder, bowel, and sexual function problems, as elicited by a decision aid, may help explain treatment selection that differs from traditional clinical recommendation.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33933504      PMCID: PMC8429102          DOI: 10.1016/j.urology.2021.04.020

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.633


  21 in total

1.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

Authors:  Matthew R Cooperberg; Peter R Carroll
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

2.  Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

Authors:  Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

3.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

4.  Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.

Authors:  Deborah R Kaye; Ji Qi; Todd M Morgan; Susan Linsell; Kevin B Ginsburg; Brian R Lane; James E Montie; Michael L Cher; David C Miller
Journal:  BJU Int       Date:  2018-10-15       Impact factor: 5.588

5.  Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer.

Authors:  Jaclyn L F Bosco; Barbara Halpenny; Donna L Berry
Journal:  Health Qual Life Outcomes       Date:  2012-09-28       Impact factor: 3.186

Review 6.  Interventions for increasing the use of shared decision making by healthcare professionals.

Authors:  France Légaré; Rhéda Adekpedjou; Dawn Stacey; Stéphane Turcotte; Jennifer Kryworuchko; Ian D Graham; Anne Lyddiatt; Mary C Politi; Richard Thomson; Glyn Elwyn; Norbert Donner-Banzhoff
Journal:  Cochrane Database Syst Rev       Date:  2018-07-19

7.  Understanding Medical Decision-making in Prostate Cancer Care.

Authors:  Rachel Thera; Dr Tracey Carr; Dr Gary Groot; Nicole Baba; Dr Kunal Jana
Journal:  Am J Mens Health       Date:  2018-06-07

8.  Implementation of prostate cancer treatment decision aid in Michigan: a qualitative study.

Authors:  Roshan Paudel; Stephanie Ferrante; Jessica Woodford; Conrad Maitland; Eric Stockall; Thomas Maatman; Giulia I Lane; Donna L Berry; Anne E Sales; James E Montie
Journal:  Implement Sci Commun       Date:  2021-03-06

Review 9.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Authors:  Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell
Journal:  J Urol       Date:  2017-12-15       Impact factor: 7.450

10.  Shared Decision-making in Urologic Practice: Results From the 2019 AUA Census.

Authors:  Giulia Ippolito Lane; Chad Ellimoottil; Lauren Wallner; William Meeks; Rachel Mbassa; James Quentin Clemens
Journal:  Urology       Date:  2020-08-07       Impact factor: 2.649

View more
  1 in total

1.  Concordance between influential adverse treatment outcomes and localized prostate cancer treatment decisions.

Authors:  Rachel A Pozzar; Niya Xiong; Fangxin Hong; Christopher P Filson; Peter Chang; Barbara Halpenny; Donna L Berry
Journal:  BMC Med Inform Decis Mak       Date:  2022-08-24       Impact factor: 3.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.